COMPARED PLASMA AND BRAIN PHARMACOKINETICS OF CLOMIPRAMINE AND ITS METABOLITE DEMETHYLCLOMIPRAMINE IN 2 STRAINS OF MICE (NMRI AND CD1)

被引:15
作者
MARTY, H
VAROQUAUX, O
FIALIP, J
CORDONNIER, P
DUROUX, E
BULACH, C
ESCHALIER, A
ADVENIER, C
PAYS, M
BASTIDE, P
机构
[1] FAC PHARM CLERMONT FERRAND,PHARACOL & PHARM CLIN LAB,BP 38,F-63001 CLERMONT FERRAND,FRANCE
[2] FAC MED CLERMONT,PHARMACOL MED LAB,F-63001 CLERMONT FERRAND,FRANCE
[3] FAC MED CLERMONT,INSERM,U19S,F-63001 CLERMONT FERRAND,FRANCE
[4] HOP ANDRE MIGNOT,PHARMACOL BIOCHIM LAB,F-78150 LE CHESNAY,FRANCE
[5] CHU PITIE SALPETRIERE,DEPT PHARMACOL,F-75634 PARIS 13,FRANCE
关键词
CLOMIPRAMINE; DEMETHYLCLOMIPRAMINE; PHARMACOKINETICS; MOUSE; STRAIN;
D O I
10.1111/j.1472-8206.1992.tb00094.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The fate of clomipramine (CMI) and its main demethylated metabolite demethylclomipramine (DCMI) was studied in two strains of Swiss mice (NMRI and CD1) after intraperitoneal injection. A study of its distribution among various tissues showed that fixation was most marked in lungs, perirenal fat and kidneys, and only moderate in the brain. The pharmacokinetic parameters of both molecules were determined in brain tissue and plasma. Absorption was rapid (t(max) CMI = 14 min), metabolism prompt (t(max) DCMI = 17 or 18 min according to the breed) and elimination rapid from both plasma and brain tissue. The first two stages were similar in the two strains, but elimination of CMI from both plasma and brain was faster in the NMRI mice (plasma t1/2 = 53 min against 165 min in the CD1 mice). Both values were well below that reported for man (mean plasma t1/2 = 24 h). The data presented can serve as a basis for designing true chronic administration protocol in animals.
引用
收藏
页码:49 / 57
页数:9
相关论文
共 43 条
[1]   USE OF OPIPRAMOL (INSIDON) FOR SUICIDE [J].
ANGST, J ;
BRANDENB. ;
HERRMANN, B .
PSYCHOPHARMACOLOGIA, 1967, 11 (02) :174-174
[2]  
BALANT LP, 1987, THERAPIE, V42, P255
[3]   ANTI-DEPRESSANTS AND OPIATES INTERACTIONS - PHARMACOLOGICAL AND BIOCHEMICAL EVIDENCES [J].
BARALDI, M ;
POGGIOLI, R ;
SANTI, M ;
VERGONI, AV ;
BERTOLINI, A .
PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1983, 15 (09) :843-857
[4]   EVALUATION OF THE LEVELS OF FREE AND TOTAL AMITRIPTYLINE AND METABOLITES IN THE PLASMA AND BRAIN OF THE RAT AFTER LONG-TERM ADMINISTRATION OF DOSES USED IN RECEPTOR STUDIES [J].
BAUMANN, P ;
GAILLARD, JM ;
JONZIERPEREY, M ;
GERBER, C ;
BOURAS, C .
PSYCHOPHARMACOLOGY, 1984, 84 (04) :489-495
[5]   DIFFERENTIAL EFFECT OF CHLORIMIPRAMINE AND NORTRIPTYLINE ON CEREBROSPINAL-FLUID METABOLITES OF SEROTONIN AND NORADRENALINE IN DEPRESSION [J].
BERTILSSON, L ;
ASBERG, M ;
THOREN, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1974, 7 (05) :365-368
[6]   CLINICAL AND BIOCHEMICAL RESULTS OF A FATAL CASE OF DESIPRAMINE INTOXICATION [J].
BICKEL, MH ;
BROCHON, R ;
FRIOLET, B ;
HERRMANN, B ;
STOFER, AR .
PSYCHOPHARMACOLOGIA, 1967, 10 (05) :431-431
[7]  
BICKEL MH, 1968, ARCH INT PHARMACOD T, V173, P433
[8]   AMITRIPTYLINE POTENTIATES MORPHINE ANALGESIA BY A DIRECT ACTION ON THE CENTRAL NERVOUS-SYSTEM [J].
BOTNEY, M ;
FIELDS, HL .
ANNALS OF NEUROLOGY, 1983, 13 (02) :160-164
[9]   PHARMACOKINETICS OF METAPRAMINE AND ITS DEMETHYLATED METABOLITES IN PLASMA AND BRAIN OF MICE [J].
BOUGEROLLE, AM ;
CHABARD, JL ;
ESCHALIER, A ;
AUMAITRE, O ;
FIALIP, J ;
DORDAIN, G ;
PETIT, J ;
BERGER, JA .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1989, 3 (05) :515-525
[10]  
BOUGEROLLE AM, 1984, THERAPIE, V39, P619